Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Denali Therapeutics (DNLI) Share-based Compensation (2017 - 2025)

Historic Share-based Compensation for Denali Therapeutics (DNLI) over the last 9 years, with Q3 2025 value amounting to $25.1 million.

  • Denali Therapeutics' Share-based Compensation rose 110.62% to $25.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $100.8 million, marking a year-over-year decrease of 291.75%. This contributed to the annual value of $102.9 million for FY2024, which is 483.25% down from last year.
  • As of Q3 2025, Denali Therapeutics' Share-based Compensation stood at $25.1 million, which was up 110.62% from $25.4 million recorded in Q2 2025.
  • Denali Therapeutics' 5-year Share-based Compensation high stood at $28.1 million for Q1 2023, and its period low was $21.0 million during Q3 2021.
  • For the 5-year period, Denali Therapeutics' Share-based Compensation averaged around $24.8 million, with its median value being $25.1 million (2025).
  • In the last 5 years, Denali Therapeutics' Share-based Compensation soared by 9497.45% in 2021 and then tumbled by 962.64% in 2025.
  • Quarter analysis of 5 years shows Denali Therapeutics' Share-based Compensation stood at $22.1 million in 2021, then rose by 14.05% to $25.2 million in 2022, then grew by 3.18% to $26.0 million in 2023, then fell by 3.5% to $25.1 million in 2024, then rose by 0.23% to $25.1 million in 2025.
  • Its Share-based Compensation was $25.1 million in Q3 2025, compared to $25.4 million in Q2 2025 and $25.2 million in Q1 2025.